To the Editor.—
There is general agreement that substances that inhibit platelet aggregation tend to be associated with a rise in platelet cyclic adenosine monophosphate (cAMP), and those that stimulate platelet-clumping with the reverse.1Epinephrine reduces platelet cAMP by inhibition of adenyl cyclase. Like epinephrine-induced platelet aggregation, this phenomenon is an α-adrenergic effect, being subject to blockade by phentolamine.2Hampton et al3 discovered that propranolol inhibited noradrenaline-induced platelet aggregation. Propranolol proved also to be a powerful inhibitor of adenosine diphosphate (ADP)-induced aggregation and of potentiating effect of epinephrine on the second phase of ADP-induced aggregation.4 It seems that this effect would be not related to β-blocking activity but to a stabilizing action on biological membranes like imipramine and related compounds.5In regard to its cardiac effects, propranolol appears to have a more evident activity on the inhibition of platelet aggregation.
Rubegni M, Provvedi D, Bellini PG. β-Blocking Agents and Platelet Aggregation. JAMA. 1974;228(4):462. doi:10.1001/jama.1974.03230290018012
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: